mucoadhesive

Medicated patch shows promise in oral cancer prevention

Source: www.healthnewsdigest.com Author: press release Researchers at The Ohio State University Comprehensive Cancer Center have developed a medicated oral patch that allows a chemoprevention drug to release directly into precancerous lesions in the mouth over an extended time. The study evaluated the drug fenretinide, a synthetic derivative of vitamin A that has highly promising anti-cancer properties. Until now, scientists have failed to achieve a therapeutic, systemic dose of fenretinide because of drug toxicity and rapid release from the body. By using a new mucoadhesive patch invented by a team from Ohio State’s Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and the University of Michigan, the researchers developed a delivery system that can provide continuous drug therapy to saliva-coated oral tissue. “The challenge with oral gels or rinses is the medication can dissolve in saliva before it penetrates into the tissue. This patch allows us to target and control drug delivery and tissue exposure,” says Dr. Susan Mallery, an oral pathologist at Ohio State’s Comprehensive Cancer Center. The patch consists of three layers: a disk saturated with fenretinide and polymers to make the drug more soluble in saliva, an adhesive ring to hold the disk in place, and a backing layer to ensure the medication stays within the patch. In their study recently published online by the journal Pharmaceutical Research, Mallery and co-investigator, Dr. Peter Larsen of Ohio State, tested the fenretinide patch using simulated saliva as well as lab animals. In [...]

Oral Cancer Foundation News Team - A2011-09-02T19:03:27-07:00September, 2011|Oral Cancer News|

Access Pharmaceuticals provides update on MuGard commercial launch in North America

Source: money.cnn.com Author: press release Access Pharmaceuticals, Inc., today provided an update on its North American commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy. Access intends to commercially launch MuGard in North America in the first quarter of 2010. Key strategic items pertaining to the launch include: Manufacturing: Access is currently working with its contract liquid manufacturer, Accupac, on initial clinical and stability batches, and expects to have initial commercial quantities available in 1Q 2010. Reimbursement: Access is working with outside regulatory consultants in developing and finalizing its reimbursement strategy as it pertains to third-party payors and Medicare/Medicaid. Clinical: Consistent with strategies employed by its global marketing partners, Access is working with key opinion leaders to develop a strategy for post-approval studies if and as needed. Access believes that its approved label indication and directions for use supports positioning MuGard as a preventative for oral mucositis caused by radiation and chemotherapy treatments, and provides for expansion into treatment of all types of oral wounds including aphthous ulcers, canker sores and traumatic ulcers, such as those caused by oral surgery. Marketing/Sales: Access has signed a deal with iMedicor to support online eMarketing efforts and education of oncologists, radiation oncologist and support staff as it pertains to oral mucositis and MuGard specifically. Access intends to build a hybrid, dedicated salesforce with oncology supportive care experience. Co-Promotion: Access continues to seek potential co-promotion arrangements with pharmaceutical and biotechnology companies in the [...]

Oral Cancer Foundation News Team - A2009-11-11T14:29:14-07:00November, 2009|Oral Cancer News|

MuGard data From UK study shows prevention of oral mucositis in head and neck cancer patients

Source: news.prnewswire.com Author: press release Access Pharmaceuticals Inc. announced today that its European partner, SpePharm, is collecting data from a post approval study of MuGard in head and neck cancer patients undergoing radiation treatment in the UK showing prevention of oral mucositis. In a multi-center study expected to enroll a total of 280 patients, patients are provided with seven weeks of MuGard therapy, and begin using MuGard one week prior to radiation treatment and then throughout the subsequent six weeks of planned therapy. The first 140 patients being treated in this assessment study have been enrolled and treated, and as of the time of the update, none of these patients have experienced any oral mucositis. "The initial feedback from SpePharm on their experience in the UK, with the first 140 patients in the assessment study, exceeds our most positive expectations," stated Jeffrey B. Davis, Access' President & CEO. "Normally, roughly 100% of patients undergoing radiation treatment for head and neck cancer experience some level of oral mucositis. This condition varies from a low level of discomfort and pain, up to Grades 3 and 4 which are debilitating to the point of patients discontinuing therapy. To see a result where all or substantially all of the patients using MuGard, and using it prophylactically, are not getting oral mucositis is extremely important with respect to treatment regimens. We believe the final data set will show that MuGard should be used prophylactically with all radiation or chemotherapy regimens that have the potential to [...]

Oral Cancer Foundation News Team - A2009-07-23T13:14:45-07:00July, 2009|Oral Cancer News|